BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
LAVAL, Quebec—November 10, 2021— BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical
company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in fireside chats at two upcoming healthcare investor
Event: Jefferies London Healthcare Conference
Date/Time: On-demand starting Thursday, November 18,
2021 at 8:00 a.m. GMT
Event: 4th Annual Evercore ISI HealthCONx
Date/Time: Wednesday, December 1, 2021 at 11:20 a.m.
Webcasts of the Jefferies and Evercore fireside chats may be accessed on the Events & Presentations page under the Investors & Media section of BELLUS
Health's website at www.bellushealth.com. Following the events, archived webcasts will be available on the Company’s website.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RCC and other hypersensitization-related
disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of RCC and chronic pruritus associated with AD.
RCC is a cough lasting more than 8 weeks despite appropriate treatment for underlying condition(s). It is estimated that there are approximately 9 million
patients in the United States suffering from RCC. RCC is associated with significant adverse physical, social, and psychosocial effects on health and quality of life. Currently, there is no specific therapy approved for RCC and treatment options
Chronic pruritus associated with AD is an irritating sensation that leads to scratching and persists for longer than 6 weeks in AD patients. It is estimated
that up to 10% of adults in the United States suffer from AD – almost all report symptoms of pruritus with over 50% of patients attributing chronic pruritus as their most burdensome symptom. Despite currently available treatments targeting AD,
there continues to be a lack of options specifically targeting the burden of pruritus in patients with AD.
FOR MORE INFORMATION, PLEASE CONTACT:
Chief Financial Officer
Source: BELLUS Health Inc.